Academic Leadership · Brilliant Journey | Dr. Liu Jiannan of Dongguan Aier Invited to Attend the National Conference on Corneal Diseases; PRP Technology Achievements Draw National Attention

Leading ophthalmologists from across the country gathered in Wuhan to explore the latest advancements in the diagnosis and treatment of corneal and ocular surface diseases. From May 8 to May 10, 2026, the 2026 Corneal Disease Academic Exchange Conference, the 25th Academic Conference on Corneal and Ocular Surface Diseases, and the 18th Annual Conference on Corneal Refractive Surgery were grandly inaugurated in Wuhan. Co-hosted by the Chinese Association of Ethnic Health and the Beijing Medical Science and Health Society, this conference is a premier academic event of the highest authority and professionalism in the fields of corneal diseases, ocular surface diseases, and refractive corneal surgery in China. It brings together leading experts, clinical leaders, and researchers from the national ophthalmology community to engage in in-depth discussions on core topics such as precision diagnosis and treatment of corneal diseases, ocular surface repair and reconstruction, standardized treatment of dry eye, and innovations in refractive corneal surgery, contributing to the continuous advancement of diagnostic and therapeutic standards for corneal and ocular surface diseases in China.

Image

Dr. Liu Jiannan from the Cornea and Ocular Surface Department at Dongguan Aier Eye Hospital, drawing on his solid professional foundation and extensive clinical experience, was invited to attend this national academic conference. He delivered a keynote academic presentation, engaging in exchanges and intellectual dialogue with ophthalmology colleagues from across the country. He systematically shared Dongguan Aier’s clinical achievements and research exploration in the diagnosis and treatment of ocular surface diseases and severe dry eye, actively participating in cutting-edge academic discussions within the industry.

Image

PRP Technology Breaks Through Bottlenecks, Solving the Challenge of Severe Dry Eye in Sjögren’s Syndrome

During the conference’s keynote session, Dr. Liu Jiannan presented a groundbreaking academic paper titled “Clinical Study on Platelet-Rich Plasma (PRP) Therapy for Severe Dry Eye Caused by Sjögren’s Syndrome.” She comprehensively explained the clinical application pathways, mechanisms of action, and real-world clinical efficacy of Platelet-Rich Plasma (PRP) technology in severe dry eye caused by Sjögren’s syndrome. Through a multi-dimensional analysis incorporating typical clinical cases, detailed diagnostic and treatment data, and core technical advantages, she fully demonstrated Dongguan Aier’s scientific innovation capabilities and ability to implement cutting-edge technologies in the diagnosis and treatment of ocular surface diseases, earning high recognition and widespread acclaim from fellow experts in attendance.

Severe dry eye caused by Sjögren’s syndrome is a common and refractory ocular surface disease in clinical practice, for which conventional physical therapy and drug treatments yield limited results. Dongguan Aier Eye Hospital has dedicated years to advancing the diagnosis and treatment of dry eye. As a pioneer in the field, the hospital introduced and successfully implemented Platelet-Rich Plasma (PRP) therapy. Leveraging the multiple growth factors released by high-concentration platelets, this approach precisely repairs damaged corneal epithelium, regulates micro-inflammation on the ocular surface, and restores a stable tear film. This breakthrough overcomes the limitations of traditional treatments, transforming the management of moderate-to-severe and refractory dry eye from mere “symptom relief” to “tissue repair and regeneration,” providing patients with severe dry eye in Dongguan and surrounding areas with a more efficient and personalized treatment plan.

Image

In February 2025, Director Ye Jianzhang’s team performed platelet-rich plasma (PRP) eye drop therapy, successfully repairing severe ocular surface damage in a patient caused by drug-induced toxic corneal disease

This presentation at a top-tier national academic conference on corneal diseases not only represents authoritative recognition of the professional capabilities of the Dongguan Aier expert team but also builds a high-level bridge for academic exchange for the hospital. By disseminating Dongguan’s clinical and research achievements in ophthalmology through a national platform while absorbing cutting-edge diagnostic and treatment concepts and innovative technologies from across the country, the hospital accumulates valuable experience for advancing clinical techniques and achieving breakthroughs in scientific research, thereby broadening its development horizons.

Image

For many years, Dongguan Aier Eye Hospital has consistently focused on the development of its corneal, ocular surface, and dry eye specialties. With a focus on academic leadership, technological innovation, and talent development, the hospital continuously optimizes its diagnostic and treatment systems, refines medical techniques, and standardizes service protocols. Through precise, personalized, and high-quality ophthalmic care, the hospital safeguards the eye health of the local community.

In the future, Dongguan Aier Eye Hospital will continue to stay at the forefront of the industry and deepen its commitment to technological innovation. By continuously introducing advanced diagnostic and treatment concepts and technologies, the hospital will further refine its comprehensive diagnostic and treatment system for dry eye and ocular surface diseases, ensuring that the people of Dongguan can access high-quality ophthalmic care that aligns with the latest national standards right in their own community.